Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 127
Filter
1.
Front Nutr ; 11: 1416753, 2024.
Article in English | MEDLINE | ID: mdl-38826578

ABSTRACT

Pea protein is one of plant proteins with high nutritional value, but its lower solubility and poor emulsifying properties limit its application in food industry. Based on wet-heating glycosylation of pea protein and inulin, effects of discharge power of atmospheric pressure plasma jet (APPJ) on structure, solubility, and emulsifying ability of pea protein-inulin glycosylation conjugate were explored. Results indicated that the APPJ discharge power did not affect the primary structure of pea protein. However, changes in secondary and spatial structure of pea protein were observed. When APPJ discharge power was 600 W, the solubility of glycosylation conjugate was 75.0% and the emulsifying stability index was 98.9 min, which increased by 14.85 and 21.95% than that of only glycosylation sample, respectively. These findings could provide technical support for APPJ treatment combination with glycosylation to enhance the physicochemical properties of plant-based proteins.

2.
Front Nutr ; 11: 1386778, 2024.
Article in English | MEDLINE | ID: mdl-38765812

ABSTRACT

The effect of atmospheric pressure plasma jet (APPJ) with different discharge power (0, 400, 600, and 800 W) on the structure and physicochemical properties of wheat starch were evaluated in this study. After APPJ treatments, significant declines in peak viscosity, breakdown viscosity, and final viscosity of wheat starch pasting parameters were observed with increase of plasma treatment power. Being treated with discharge power of 800 W, the PV and BD value of wheat starch paste significantly dropped to 2,578 and 331 cP, respectively. Apparently, APPJ could raise the solubility of wheat starch, while reduce the swelling capacity, and also lower the G' and G″ value of wheat starch gel. Roughness and apparent scratch was observed on the surface of the treated wheat starch granules. Although APPJ treatment did not alter wheat starch's crystallization type, it abated the relative crystallinity. APPJ treatment might be useful in producing modified wheat starch with lower viscosity and higher solubility.

3.
Food Res Int ; 169: 112749, 2023 07.
Article in English | MEDLINE | ID: mdl-37254375

ABSTRACT

Vitamin C (VC), vitamin E (VE) and ß-carotene (ßC) are representative dietary antioxidants, which exist in daily diet and can increase the antioxidant capacity of body fluids, cells and tissues. The health benefits of vitamins like VC, VE and ßC are widely demonstrated. Given that the strong associations between the gut microbiota and host health or a range of diseases has been extensively reported, it is important to explore the modulatory effects of known vitamins on the gut microbiota. Herein, this article reviews the effects of VC, VE and ßC on the gut microbiota. Totally, 19 studies were included, of which eight were related to VC, nine to VE, and six to ßC. Overall, VC, VE and ßC can provide health benefits to the host by modulating the composition and metabolic activity of the gut microbiota, improving intestinal barrier function and maintaining the normal function of the immune system. Two perspectives are proposed for future studies: i) roles of known antioxidant activity of vitamins in regulating the gut microbiota and its molecular mechanism need to be further studied; ii) causal relationships between the regulatory effects of vitamins on gut microbiota and host health still remains to be further verified.


Subject(s)
Gastrointestinal Microbiome , Vitamin E , Ascorbic Acid/metabolism , beta Carotene/metabolism , Vitamins , Antioxidants/metabolism , Vitamin A/metabolism , Vitamin K
4.
Nat Commun ; 14(1): 477, 2023 01 30.
Article in English | MEDLINE | ID: mdl-36717576

ABSTRACT

Silymarin has been used for improving hepatic damage and lipid disorders, but its action mechanism remains to be clarified. Here, we investigate the contributions of the gut microbiota to the improvement of liver lipid metabolism by silymarin. We find i) strong and significant microbial shifts upon silymarin but not silibinin treatment; ii) over 60% variations of liver fat are explained by silymarin-induced bacterial B12 production in male rats but not in male germ-free mice; iii) fecal microbiota transplantation confirms their protective roles against liver fat accumulation; iv) upregulation of one-carbon metabolism and fatty acid degradation pathways are observed based on the liver transcriptome analyses; and v) in humans the delta changes of serum B12 associate negatively with the fluctuations of serum triglycerides. Overall, we reveal a mechanism of action underpinning the lipid-lowering effect of silymarin via the gut microbiota and its vitamin B12 producing capabilities.


Subject(s)
Silymarin , Humans , Rats , Male , Mice , Animals , Silymarin/pharmacology , Silymarin/metabolism , Vitamin B 12/pharmacology , Vitamin B 12/metabolism , Antioxidants/metabolism , Liver/metabolism , Lipid Metabolism , Lipids/pharmacology
5.
Crit Rev Food Sci Nutr ; 63(20): 4675-4686, 2023.
Article in English | MEDLINE | ID: mdl-34871105

ABSTRACT

Phytosterols are bioactive food components widely present in cell membranes of plants, especially in nuts and oilseeds. In recent years, many studies have shown that phytosterols possess therapeutic potentials for nonalcoholic fatty liver disease (NAFLD). This review summarizes the effects of phytosterols from in vitro and in vivo studies to lower the levels of total cholesterol (TC) and triglycerides (TG), and the evidence supporting the potential of phytosterols against NAFLD. The potential mechanisms by which phytosterols improve NAFLD may include (i) competition with cholesterol; (ii) regulation of key factors involved in cholesterol and TG metabolism; and (iii) inhibition of liver inflammation and (iv) regulation of liver fatty acid composition. In summary, phytosterols are potential natural ingredients with good safety profile against NAFLD, which deserve more future studies.


Subject(s)
Non-alcoholic Fatty Liver Disease , Phytosterols , Humans , Non-alcoholic Fatty Liver Disease/drug therapy , Phytosterols/pharmacology , Cholesterol/metabolism , Triglycerides/metabolism , Liver
6.
Life Sci ; 310: 121110, 2022 Dec 01.
Article in English | MEDLINE | ID: mdl-36272466

ABSTRACT

AIMS: Glycyrrhizic acid is a natural anti-non-alcoholic fatty liver disease (NAFLD) compound isolated from licorice, while its action mechanism deserves to be fully elucidated. MATERIALS AND METHODS: Enlightened by the widely discovered associations between the NAFLD and gut microbiota, this study aimed to explore whether glycyrrhizic acid, licorice flavonoids, and licorice extract can regulate the gut microbiota of rats fed a high-fat diet. KEY FINDINGS: It was found that glycyrrhizic acid, licorice flavonoids, and licorice extract could significantly reduce the level of triglycerides in the liver of NAFLD model rats, and the effect of glycyrrhizic acid was stronger than licorice flavonoids and licorice extract. Moreover, they caused significant changes in the structural composition of the gut microbiota. Correlation analysis showed that the regulation of hepatic total cholesterol and triglyceride levels by glycyrrhizic acid treatment was closely related to the decrease of the relative abundances of Lachnospiraceae, Coriobacteriaceae, Blautia, and Collinsella and the increase of the relative abundances of Romboutsia and Turicibacter on the gut microbiota. Meanwhile, the functional predictive analysis of the gut microbiota indicated that the function of carbohydrate transport and metabolism was significantly decreased by drugs treatment, which might contribute to the decrease of fat accumulation in the liver of rats. SIGNIFICANCE: In conclusion, this study revealed the ameliorating effects of glycyrrhizic acid, licorice flavonoids, and licorice extract on NAFLD, and suggested that the effect of glycyrrhizic acid on NAFLD may be related to the improvement of the dysbiosis of gut microbiota.


Subject(s)
Gastrointestinal Microbiome , Non-alcoholic Fatty Liver Disease , Rats , Animals , Mice , Diet, High-Fat/adverse effects , Glycyrrhizic Acid/metabolism , Non-alcoholic Fatty Liver Disease/metabolism , Liver/metabolism , Plant Extracts/therapeutic use , Flavonoids/therapeutic use , Mice, Inbred C57BL
7.
Food Funct ; 13(12): 6665-6673, 2022 Jun 20.
Article in English | MEDLINE | ID: mdl-35647710

ABSTRACT

The potential of micronutrients, including vitamins and minerals, to prevent Alzheimer's disease (AD) has attracted much attention. However, the causal associations between micronutrient levels or supplements and AD risk remain unclear. We performed a two-sample Mendelian randomization (2SMR) analysis to evaluate the causal associations between micronutrient levels and supplements and AD risk. A total of 60 genome-wide association studies (GWAS) related to five types of vitamins (vitamins A, B, C, D, and E) and seven types of minerals (magnesium, calcium, iron, copper, zinc, selenium, and phosphorus) were included. For vitamins, using the data source provided by two GWAS, the analysis of 2SMR indicated that the vitamin D level was causally associated with a decreased risk of AD (IVW, OR: 0.474, 95%CI: 0.269-0.834, P-value = 0.010; OR: 0.857, 95%CI: 0.748-0.982, P-value = 0.027), while no effect of vitamin D supplement was observed. Currently, available data do not support the causal associations between the other four types of vitamins/supplements and AD risk. As for minerals, the copper level acted as a causal protective factor for AD risk (IVW, OR: 0.865, 95%CI: 0.751-0.998, P-value = 0.046). In conclusion, the present analysis indicated that among the vitamins and minerals, vitamin D and copper levels exhibited negative causal associations with AD risk, which may help in better use of micronutrients to prevent AD and require further verification by further studies.


Subject(s)
Alzheimer Disease , Selenium , Alzheimer Disease/genetics , Copper , Genome-Wide Association Study , Humans , Mendelian Randomization Analysis , Micronutrients , Vitamin A , Vitamin D , Vitamins
8.
Cell Biosci ; 12(1): 28, 2022 Mar 10.
Article in English | MEDLINE | ID: mdl-35272707

ABSTRACT

BACKGROUND: Despite accumulating epidemiological studies support that diabetes increases the risk of Alzheimer's disease (AD), the causal associations between diabetes and AD remain inconclusive. The present study aimed to explore: i) whether diabetes is causally related to the increased risk of AD; ii) and if so, which diabetes-related physiological parameter is associated with AD; iii) why diabetes drugs can be used as candidates for the treatment of AD. Two-sample Mendelian randomization (2SMR) was employed to perform the analysis. RESULTS: Firstly, the 2SMR analysis provided a suggestive association between genetically predicted type 1 diabetes (T1D) and a slightly increased AD risk (OR = 1.04, 95% CI = [1.01, 1.06]), and type 2 diabetes (T2D) showed a much stronger association with AD risk (OR = 1.34, 95% CI = [1.05, 1.70]). Secondly, further 2SMR analysis revealed that diabetes-related physiological parameters like fasting blood glucose and total cholesterol levels might have a detrimental role in the development of AD. Thirdly, we obtained 74 antidiabetic drugs and identified SNPs to proxy the targets of antidiabetic drugs. 2SMR analysis indicated the expression of three target genes, ETFDH, GANC, and MGAM, were associated with the increased risk of AD, while CPE could be a protective factor for AD. Besides, further PPI network found that GANC interacted with MGAM, and further interacted with CD33, a strong genetic locus related to AD. CONCLUSIONS: In conclusion, the present study provides evidence of a causal association between diabetes and increased risk of AD, and also useful genetic clues for drug development.

9.
Drug Discov Today ; 27(5): 1464-1473, 2022 05.
Article in English | MEDLINE | ID: mdl-35104620

ABSTRACT

Extracellular signal-regulated kinases 1 and 2 (ERK1/2) are important members of the RAS signaling pathway. They are abnormally expressed in many diseases and, thus, are considered key therapeutic targets of human diseases. In this review, we summarize the importance of the ERK1/2 signaling pathway in the treatment of different diseases and inhibitors of ERK1/2 in clinical or preclinical research. We also discuss the main approaches used to discover ERK inhibitors, including the application and advantages of computer-aided drug design (CADD) approaches.


Subject(s)
MAP Kinase Signaling System , Protein Kinase Inhibitors , Drug Design , Enzyme Inhibitors/pharmacology , Extracellular Signal-Regulated MAP Kinases , Humans , Phosphorylation , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/therapeutic use , Signal Transduction
10.
J Pharm Anal ; 11(5): 555-563, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34765268

ABSTRACT

Vine tea has been used as an herbal tea by several ethnic minorities for hundreds of years in China. Flavonoids, a kind of indispensable component in a variety of nutraceutical, pharmaceutical and cosmetic applications, are identified to be the major metabolites and bioactive ingredients in vine tea. Interestingly, vine tea exhibits a wide range of significant bioactivities including anti-oxidant, anti-inflammatory, anti-tumor, antidiabetic, neuroprotective and other activities, but no toxicity. These bioactivities, to some extent, enrich the understanding about the role of vine tea in disease prevention and therapy. The health benefits of vine tea, particularly dihydromyricetin and myricetin, are widely investigated. However, there is currently no comprehensive review available on vine tea. Therefore, this report summarizes the most recent studies investigating bioactive constituents, pharmacological effects and possible mechanisms of vine tea, which will provide a better understanding about the health benefits and preclinical assessment of novel application of vine tea.

11.
Appl Microbiol Biotechnol ; 105(20): 7721-7730, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34596721

ABSTRACT

The steadily increasing prevalence of Alzheimer's disease (AD) worldwide and the lack of effective therapeutic agent attract novel therapeutic approach in recent years. In view of the close relationships between gut microbiota and AD, probiotics have been suggested as potential therapeutic options for AD in recent years. The present review discussed the research progresses concerning the effects of probiotics administration to combat AD. A total of 35 studies, including 26 animal model studies and 9 human studies, were included herein. Among the 26 animal model studies, 24 used mice model, and 2 used Caenorhabditis elegans and Drosophila melanogaster AD models, respectively. As for probiotics, a total of 13 studies employed single-strain probiotic, and the rest studies used multi-strain probiotics (ranged from 2 to 9 probiotic strains), 4 used probiotic-fermented milk or probiotic-fermented soybean, 2 studies used engineered probiotic strain, and 4 studies focused on the combined effect of probiotics with AD drug memantine, selenium, or exercise. Bifidobacterium and Lactobacillus species were the most frequently used probiotics in the included studies. Overall, currently available studies showed that probiotic administration conferred neuroprotective benefits and could attenuate cognitive deficits and modulate gut microbiota dysbiosis, which may be related to oxidative and inflammatory pathways. Several perspectives on future studies on this topic are proposed. Thus, probiotics seem to be an attractive approach to combat AD, which deserves to be further studied by well-designed large-scale clinical studies. KEY POINTS: •We discussed the recent progresses concerning the effects of probiotics administration to combat AD. •A total of 35 associated studies consisted of 26 animal model studies and 9 human studies were included. •Most studies found that probiotic administration conferred neuroprotective benefits and could attenuate cognitive deficits.


Subject(s)
Alzheimer Disease , Gastrointestinal Microbiome , Probiotics , Alzheimer Disease/drug therapy , Animals , Bifidobacterium , Drosophila melanogaster , Mice
12.
Cell Rep ; 36(9): 109641, 2021 08 31.
Article in English | MEDLINE | ID: mdl-34469716

ABSTRACT

The relationship between poor in vivo bioavailability and effective pharmacological activity are not yet fully clarified for many flavonoids. The analysis of flavonoids-induced alterations in the gut microbiota represents a promising approach to provide useful clues to elucidate the mechanism of action. Here, we investigate the effect of myricetin supplementation on high-fat-diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in rats and explore the associations with the gut microbiota through high-throughput analyses. The 12-week myricetin supplementation and fecal microbiota transplantation outcomes suggest that myricetin significantly slows the development of NAFLD. Meanwhile, the anti-NAFLD effects of myricetin are associated with the modulation of the gut microbiota composition. Myricetin reduces hepatic lipid synthesis and inflammation through modulations in fecal butyric-acid-related gut microbiota and protection of the gut barrier function. This study may facilitate the elucidation of the action mechanism of flavonoids with low bioavailability.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Bacteria/drug effects , Flavonoids/pharmacology , Gastrointestinal Microbiome/drug effects , Hepatitis/prevention & control , Lipogenesis/drug effects , Liver/drug effects , Non-alcoholic Fatty Liver Disease/prevention & control , Animals , Bacteria/growth & development , Bacteria/metabolism , Biomarkers/blood , Butyrates/metabolism , Diet, High-Fat , Disease Models, Animal , Dysbiosis , Fecal Microbiota Transplantation , Hep G2 Cells , Hepatitis/metabolism , Hepatitis/microbiology , Humans , Inflammation Mediators/blood , Lipids/blood , Liver/metabolism , Male , Non-alcoholic Fatty Liver Disease/metabolism , Non-alcoholic Fatty Liver Disease/microbiology , Rats, Wistar
13.
Bioorg Chem ; 112: 104966, 2021 07.
Article in English | MEDLINE | ID: mdl-33991837

ABSTRACT

Increasing intestinal barrier function is one of the basic methods to suppress inflammation in the progression from simple steatosis (SS) to nonalcoholic steatohepatitis (NASH). Luteolin exists widely in vegetables, fruits and natural herbs and has various biological activities, including benefits on nonalcoholic fatty liver disease (NAFLD). However, its regulatory effects on the gut microbiota and involvement in its biological activities remain to be investigated. We fed rats a high-fat diet containing 0.5% luteolin for 12 weeks and determined the effects of luteolin on lipid metabolism, inflammation, and the gut microbiota. Supplementation with luteolin for 12 weeks significantly reduced blood lipids and hepatic lipid levels and improved liver fat accumulation and inflammation. Moreover, supplementation with luteolin led to the significant enrichment of more than 10% of gut bacterial species, which contributed to increase the abundance of ZO-1, reduce intestinal permeability, reduce plasma lipopolysaccharide, and inhibit the TLR4/NF-κB pathway. In summary, the anti-inflammatory effect of luteolin might be related to changes in the gut microbiota and contribute to preventing the progression from SS to NASH. Our research provides new insights into the anti-inflammatory mechanism of luteolin and supports its use as a dietary supplement for NAFLD patients.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Fatty Liver/prevention & control , Gastrointestinal Microbiome/drug effects , Luteolin/pharmacology , Non-alcoholic Fatty Liver Disease/prevention & control , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/chemistry , Diet, High-Fat/adverse effects , Dietary Supplements , Dose-Response Relationship, Drug , Fatty Liver/pathology , Luteolin/administration & dosage , Luteolin/chemistry , Molecular Structure , Non-alcoholic Fatty Liver Disease/pathology , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship
14.
PLoS One ; 16(2): e0247248, 2021.
Article in English | MEDLINE | ID: mdl-33600459

ABSTRACT

The conversion of cellular prion protein (PrPC) to disease-provoking conformer (PrPSc) is crucial in the pathogenesis of prion diseases. Heparin has been shown to enhance mammalian prion protein misfolding. As spontaneous prion disease has not been reported in non-mammalian species, such as chicken, it is interesting to explore the influence of heparin on the conversion of chicken prion protein (ChPrP). Herein, we investigated the influences of heparin on biochemical properties of full-length recombinant ChPrP, with murine prion protein (MoPrP) as control. The results showed that at low heparin concentration (10 µg/mL), a great loss of solubility was observed for both MoPrP and ChPrP using solubility assays. In contrast, when the concentration of heparin was high (30 µg/mL), the solubility of MoPrP and ChPrP both decreased slightly. Using circular dichroism, PK digestion and transmission electron microscopy, significantly increased ß-sheet content, PK resistance and size of aggregates were observed for MoPrP interacted with 30 µg/mL heparin, whereas 30 µg/mL heparin-treated ChPrP showed less PK resistance and slight increase of ß-sheet structure. Therefore, heparin can induce conformational changes in both MoPrP and ChPrP and the biochemical properties of the aggregates induced by heparin could be modified by heparin concentration. These results highlight the importance of concentration of cofactors affecting PrP misfolding.


Subject(s)
Endopeptidase K/metabolism , Heparin/pharmacology , Prion Proteins/chemistry , Prion Proteins/genetics , Animals , Chickens , Circular Dichroism , Mice , Microscopy, Electron, Transmission , Models, Molecular , Prion Proteins/metabolism , Protein Conformation , Protein Conformation, beta-Strand , Proteolysis , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Solubility
15.
J Alzheimers Dis ; 80(1): 271-281, 2021.
Article in English | MEDLINE | ID: mdl-33523009

ABSTRACT

BACKGROUND: Identifying modifiable risk factors, such as obesity, to lower the prevalence of Alzheimer's disease (AD) has gained much interest. However, whether the association is causal remains to be evaluated. OBJECTIVE: The present study was designed: 1) to make a quantitative assessment of the association between obesity and AD; 2) to validate whether there was a causal association between them; and 3) to provide genetic clues for the association through a network-based analysis. METHODS: Two-sample Mendelian randomization (2SMR) analysis, meta-analysis, and protein-protein interaction (PPI) network analysis, were employed. RESULTS: Firstly, the meta-analysis based on 9 studies comprising 6,986,436 subjects indicated that midlife obesity had 33%higher AD odds than controls (OR = 1.33, 95%CI = [1.03, 1.62]), while late-life obesity were inversely associated with AD risk (OR = 0.57, 95%CI = [0.47, 0.68]). Secondly, 2SMR analysis indicated that there was no causal association between them. Thirdly, CARTPT was identified to be shared by the anti-obesity drug targets and AD susceptibility genes. Further PPI network analysis found that CARTPT interacted with CD33, a strong genetic locus linked to AD. Finally, 2SMR analysis showed that CNR1 could be a protective factor for AD. CONCLUSION: Multiple bioinformatic analyses indicated that midlife obesity might increase the risk of AD, while current evidence indicated that there was no causal association between them. Further, CARTPT might be an important factor linking the two disease conditions. It could help to better understand the mechanisms underlying the associations between obesity and AD.


Subject(s)
Alzheimer Disease/complications , Alzheimer Disease/epidemiology , Obesity/complications , Obesity/epidemiology , Aged , Aged, 80 and over , Alzheimer Disease/genetics , Anti-Obesity Agents/pharmacology , Causality , Computational Biology , Female , Gene Regulatory Networks , Genetic Predisposition to Disease/genetics , Genome-Wide Association Study , Humans , Male , Mendelian Randomization Analysis , Middle Aged , Obesity/genetics , Polymorphism, Single Nucleotide , Proteomics , Risk Factors , Sialic Acid Binding Ig-like Lectin 3/genetics
16.
Appl Microbiol Biotechnol ; 105(3): 1007-1015, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33449129

ABSTRACT

Transition metal ions are essential micronutrients for all living organisms and exert a wide range of effects on human health. The uptake of transition metal ions occurs primarily in the gastrointestinal tract, which is colonized by trillions of bacterial cells. In recent years, increasing studies have indicated that transition metals have regulatory effects on the gut microbiota. In view of the significant effect of the gut microbiota on human health and involvement in the pathogenesis of a wide range of diseases, in this paper, we provide a comprehensive discussion on the regulatory effects of four kinds of transition metal ions on the gut microbiota. A total of 20 animal model and human studies concerning the regulatory effects of four types of transition metal ions (i.e., iron, copper, zinc, and manganese) on gut microbiota were summarized. Both the deficiency and supplementation of these transition metal ions on the gut microbiota were considered. Furthermore, the potential mechanisms governing the regulatory effects of transition metal ions on the gut microbiota were also discussed. KEY POINTS : • Regulatory effects of iron, copper, zinc, and manganese on gut microbiota were reviewed. • Both deficiency and supplementation of metal ions on gut microbiota were considered. • Mechanisms governing effects of metal ions on gut microbiota were discussed.


Subject(s)
Gastrointestinal Microbiome , Animals , Copper , Dietary Supplements , Humans , Iron , Zinc
17.
Brief Bioinform ; 22(3)2021 05 20.
Article in English | MEDLINE | ID: mdl-32951050

ABSTRACT

In view of great difficulties in the pathogenesis analysis of Alzheimer's disease (AD) presently, profiling the modifiable risk factors is crucial for early detection and intervention of AD. However, the causal associations among them have yet to be identified, and the effective integration and application of these data also remain considerable challenges due to the lack of efficient collection and analysis procedures. To address this issue, we performed comprehensive analyses by two-sample Mendelian randomization (2SMR) and established the AlzRiskMR database (https://github.com/SDBMC/RiskFactors2AD). Four 2SMR analysis methods, including inverse variance weighted (IVW), MR-Egger, weighted median, and weighted mode, were used for the complementary calculation to test the reliability of the results. The database currently comprises 1870 sets of data of Genome-Wide Association Studies (GWAS) from the MR-Base and NHGRI-EBI GWAS Catalog database. AlzRiskMR database not only estimates causal associations between modifiable risk factors and AD but also offers a useful and timely resource for early intervention of AD development incidence.


Subject(s)
Alzheimer Disease/genetics , Databases, Genetic , Genome-Wide Association Study/methods , Internet , Polymorphism, Single Nucleotide , Alzheimer Disease/diagnosis , Alzheimer Disease/epidemiology , Causality , Female , Genome-Wide Association Study/statistics & numerical data , Humans , Male , Mendelian Randomization Analysis/methods , Risk Factors
18.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-908775

ABSTRACT

Vine tea has been used as an herbal tea by several ethnic minorities for hundreds of years in China.Flavonoids,a kind of indispensable component in a variety of nutraceutical,pharmaceutical and cosmetic applications,are identified to be the major metabolites and bioactive ingredients in vine tea.Interest-ingly,vine tea exhibits a wide range of significant bioactivities including anti-oxidant,anti-inflammatory,anti-tumor,antidiabetic,neuroprotective and other activities,but no toxicity.These bioactivities,to some extent,enrich the understanding about the role of vine tea in disease prevention and therapy.The health benefits of vine tea,particularly dihydromyricetin and myricetin,are widely investigated.However,there is currently no comprehensive review available on vine tea.Therefore,this report summarizes the most recent studies investigating bioactive constituents,pharmacological effects and possible mechanisms of vine tea,which will provide a better understanding about the health benefits and preclinical assessment of novel application of vine tea.

19.
Virol J ; 17(1): 105, 2020 07 14.
Article in English | MEDLINE | ID: mdl-32664965

ABSTRACT

BACKGROUND: Liao ning virus (LNV) is a member of the genus Seadornavirus, family Reoviridae and has been isolated from kinds of vectors in Asia and Australia. However, there are no systematic studies describe the molecular genetic evolution and migration of LNVs. With the development of bioinformatics, viral genetic data combining the information of virus isolation time and locations could be integrated to infer the virus evolution and spread in nature. METHODS: Here, a phylogenetic and phylogeographic analysis using Bayesian Markov chain Monte Carlo simulations was conducted on the LNVs isolated from a variety of vectors during 1990-2014 to identify the evolution and migration patterns of LNVs. RESULTS: The results demonstrated that the LNV could be divided into 3 genotypes, of which genotype 1 mainly composed of LNVs isolated from Australia during 1990 to 2014 and the original LNV strain (LNV-NE97-31) isolated from Liaoning province in northern China in 1997, genotype 2 comprised of the isolates all from Xinjiang province in western China and genotype 3 consisted the isolates from Qinghai and Shanxi province of central China. LNVs emerged about 272 years ago and gradually evolved into three lineages in the order genotype 1, genotype 2 and genotype 3. Following phylogeographic analysis, it shows genotype 1 LNVs transmitted from Australia (113°E-153°E,10°S-42°S) to Liaoning province (118°E-125°E,38°N-43°N) in Northeast Asian continent then further spread across the central part of China to western China (75°E-95°E,35°N-50°N). CONCLUSION: LNVs were initially isolated from Liaoning province of China in the Northeast Asia, however, the present study revealed that LNVs were first appeared in Australia in the South Pacific region and transmitted to mainland China then rapidly spread across China and evolved three different genotypes. The above results suggested that LNV had the characteristics of long-distance transmission and there were great genetic diversity existed in the LNV population. Notably, current information of 80 strains of LNVs are limited. It is of great importance to strengthen the surveillance of LNVs to explore its real origin in nature and monitoring of the LNVs' population variation and maintain vigilance to avoid LNV breaking through the species barrier and further clarify its relationship to human and animal infection.


Subject(s)
Evolution, Molecular , Genotype , Phylogeny , Reoviridae/genetics , Animals , Australia , Bayes Theorem , China , Culicidae/classification , Culicidae/virology , Phylogeography , Reoviridae/classification , Sequence Analysis, DNA
20.
Trends Mol Med ; 26(6): 597-614, 2020 06.
Article in English | MEDLINE | ID: mdl-32470386

ABSTRACT

Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) represent two major health burdens with steadily increasing prevalence and accumulating evidence indicates a close relationship between the two disorders. In view of their similar pathogenesis, the potential of T2DM drugs for the treatment of AD has attracted considerable attention in recent years, with inspiring outcomes. Here, we provide a comprehensive overview of the effects of a total of 14 individual drugs (among which are seven T2DM drug types) against AD. Further, we discuss the potential action mechanisms of these T2DM drugs against AD. We argue that these findings may open novel avenues for AD drug discovery, drug target identification, and cotreatment of the two disorders.


Subject(s)
Alzheimer Disease/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/pharmacology , Hypoglycemic Agents/therapeutic use , Animals , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...